BACKGROUND During the past decade, in the United States, an increasing number of hepatitis B outbreaks have been reported in assisted living facilities (ALFs) as a result of breaches in infection control practices. We evaluated the seroprotection rates conferred by hepatitis B vaccine among older adults during a response to an outbreak that occurred in multiple ALFs and assessed the influence o...

Objective To determine seroprotection and vaccine response rates produced by a diphtheria–tetanus–acellular pertussis–inactivated poliovirus–Haemophilus influenzae type-b conjugate (DTaP–IPV//PRP~T) vaccine containing a polyribosyl-ribitol-phosphate (PRP)– tetanus toxoid conjugate (PentaximTM) and given with a hepatitis B vaccine. Methods In this multicentre open-label trial, 424 infants who re...

BACKGROUND Vaccinating infants against hepatitis B virus (HBV) is the most effective way of preventing the disease. However, since HBV exposure can increase during adolescence, it is essential that antibody persistence is maintained. We evaluated the antibody persistence and immune memory against hepatitis B, in 12-13 y olds who had received complete primary + booster vaccination with diphtheri...

BACKGROUND Viral hepatitis B (VHB) is an occupational risk for dentists. It is necessary that dental students start clinical practice immunized with the vaccine, response monitored and informed about the means of transmission of the disease. Rarely, there are studies, which evaluate concomitantly knowledge of these academics and their vaccine situation. OBJECTIVES To evaluate the knowledge ab...

Neonates of hepatitis B surface antigen (HBsAg) positive and hepatitis B encoded antigen (HBeAg) positive mothers received 10 micrograms of recombinant hepatitis B vaccine at months 0, 1, 6, or 0, 1, 2, 12, with or without immunoglobulin at birth, and were followed up to the age of 8 years for HBsAg, anti-HBc, and anti-HBs. Some were boosted at month 60. The overall vaccine protection at month ...

Abstract Background There is a decrease in vaccine-specific antibody to certain vaccine-preventable diseases in children after chemotherapy, but the frequency of non-immune patients is not clear. In the present case-control study, was taken under investigation protection level to Hepatitis B infection in children 6 months after completing chemotherapy. Materials and Methods In this study 6...

Two antigen-antibody systems were Out of 42 sera from patients with acute viral hepatitis 33 were positive for HBsAg,all HBsAg positive individuals possessed anti-HBc. From 11 blood donors  sera 8 were positive for HBsAg and 9 were Positive for anti-HBc;2 leprosy sera were tested,both of them were positive for HBsAg and anti-HBc. 5 miscellaneous sam­ples,z·were positive for HBsAg and anti-HBc...

background: hepatitis b virus (hbv) fails to produce appropriate immune responses in some healthy individuals; thus, different strategies have been adopted to promote immune responses. the current study aimed at evaluating the efficacy of hbv vaccine coadministered with tetanus-diphtheria (td) vaccine compared with hbv vaccine in healthy individuals through measuring hepatitis b surface antibod...

background: hepatitis b virus (hbv) infection is an endemic infection in nigeria. health care workers (hcws) are at risk of occupational exposures to hbv-infected blood and body fluids. objective: to determine the prevalence and determinants of hbv vaccine coverage among hcws in two teaching hospitals in nigeria. methods: this cross-sectional study was undertaken in 2011 and 2012 in two teachin...

BACKGROUND Hepatitis B is an important public health concern in South Africa (SA). The hepatitis B virus (HBV) vaccine was introduced into the South African Expanded Programme on Immunisation (EPI-SA) in 1995. There is no 'catch-up' programme in place. The duration of protection after hepatitis B vaccination in the SA population is unknown. Waning of vaccine-induced immunity leaves people at ri...